ACS Pharmacology & Translational Science · 2019 · 67 citations · 46 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyStructure-activity RelationshipsCannabinoid PharmacologyLigand BindingReceptor PharmacologyReceptor-ligand InteractionsAgonist ActivityBiased AgonismCannabinoid AgonistsCannabinoid Receptor PharmacologyCannabinoid Structure-activity RelationshipsLigand Design
Cannabinoid receptor 1 (CB1) is a key drug target for a number of diseases, including metabolic syndromes and neuropathic pain. Most of the typical cannabinoid ligands provoke psychotropic side effects that impair their therapeutic utility. As of today, it is not yet clearly known which structural features of cannabinoid ligands determine a preference toward specific signaling pathways. Distinct bioassays are typically used to elucidate signaling preferences. However, these are often based on different cell lines and use different principles and/or read-outs, which makes straightforward assessment of “ligand bias” difficult. Within this context, this study is the first to investigate ligand bias among synthetic cannabinoid receptor agonists (SCRAs) in as closely analogous conditions as possible, by applying a new functional complementation-based assay panel to assess the recruitment of Gαi protein or β-arrestin2 to CB1. In a panel of 21 SCRAs, chosen to cover a broad diversity in chemical structures, distinct, although often subtle, preferences toward specific signaling pathways were observed. Relative to CP55940, here considered as a “balanced” reference agonist, most of the selected SCRAs (e.g., 5F-APINACA, CUMYL-PEGACLONE, among others) displayed preferred signaling through the β-arrestin2 pathway, whereas MMB-CHMICA could serve as a potential “balanced” agonist. Interestingly, EG-018 was the only SCRA showing a significant (10-fold) preference toward G protein over β-arrestin2 recruitment. While it is currently unclear what this exactly means in terms of abuse potential and/or toxicity, the approach proposed here may allow construction of a knowledge base that in the end may allow better insight into the structure–“functional” activity relationship of these compounds. This may aid the development of new therapeutics with less unwanted psychoactive effects.
46
Determination and characterization of a cannabinoid receptor in rat brain.
William A. Devane, F A Dysarz, M R Johnson et al. · Molecular Pharmacology · 1988 · 2.4K citations
Medicine, Neuroscience, Pharmacology +12
Conformational biosensors reveal GPCR signalling from endosomes
Roshanak Irannejad, Jin C. Tomshine, Jon R. Tomshine et al. · Nature · 2013 · 840 citations · Full text
Scott M. DeWire, Dennis S. Yamashita, David H. Rominger et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 655 citations
Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics
Cullen L. Schmid, Nicole Kennedy, Nicolette C. Ross et al. · Cell · 2017 · 561 citations · Full text
RETRACTED ARTICLE: Crystal structures of agonist-bound human cannabinoid receptor CB1
Tian Hua, Kiran Vemuri, Spyros P. Nikas et al. · Nature · 2017 · 505 citations · Full text